Does VTRS pay a dividend and is it safe?

Viatris Inc. (VTRS) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / VTRS / dividends

ALNY (53) INSM (44) UTHR (83) ROIV (42) ⌘ Pro Terminal →

Viatris Inc. (VTRS) Dividend Safety Gauge & 10-Year DRIP Compounder

$18.67 -1.92% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $18.57

Viatris Inc. (VTRS) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $21.86B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VTRS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VTRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Viatris Inc. (NASDAQ: VTRS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $18.67 (-1.92% 1D, market cap $21.86B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, VTRS ranks #184 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VTRS compare to ALNY and INSM in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VTRS carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 35.2%, and ROIC of -8.1%. By comparison, ALNY (Alnylam Pharmaceuticals Inc.) holds a D+ grade (53/100 RQD, P/E 74.2x, ROIC 21.3%, cap $22.10B) and INSM (Insmed Incorporated) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $24.70B). Among the 5-stock peer group, UTHR leads on earnings multiple (19.1x) while ALNY leads on capital efficiency (21.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VTRS?

▼

Per VTRS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001792044), Viatris Inc. generated $14.25B in revenue (-3.0% YoY), $0 in net income, and $1.94B in free cash flow against $37.19B in total assets and $12.48B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $18.57 (-0.54%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 13.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-0.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VTRS)Realized 20D OHLCV Swing Band: ±5.4%

Deterministic 5-Pillar Attribution (57/100 Composite)

🔍 WHY VTRS SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (32% of score)

20D Institutional Volume Accumulation (±5.4% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (21% of score)

FRED Regime × Technicals: 91% of 52W Range • RSI-14 at 62.5 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Cash Engine Quality7/20 pts (-13 pt drag)

Capital intensity & 0% operating margin leave 13 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$17.44+5.8% Next Q

Q2 (-2Q)

Grade C-$18.45+1.7% Next Q

Q3 (-1Q)

Grade C-$18.77-0.5% Next Q

Current

Grade D+$18.67-0.2% Hist 90D α

Trajectory: D (49) → D+ (57)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VTRS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, VTRS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 32.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($17.61) or 200D SMA ($15.99) invalidates the momentum regime and cuts Target Base ($18.59) toward Bear Floor ($14.50).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VTRS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VTRS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 57%NO 43%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VTRS)

✓Walkthrough of VTRS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VTRS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +22.83%▲ ASCENDING CHANNEL

2026-11-03O $19.20H $19.20L $18.67C $18.67VOL 8.79M

RES: $19.56SUP: $17.25SMA50: $17.61SMA200: $15.99

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VTRS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VTRS Butterfly Map → + Track VTRS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

25.5%/yr Implied 5Y Growth

vs. -3.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VTRS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VTRS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VTRS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VTRS)

Health Care Rank #184 of 1016 ⚔️ ALNY vs VTRS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VTRS vs. ALNY, INSM, UTHR, ROIV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Viatris Inc. (VTRS) ranks #184 by composite RQD confidence (57/100, grade D+) and #70 by equity capitalization ($21.86B). Within this direct 5-issuer industry benchmark cohort, UTHR leads on earnings valuation at 19.1x trailing P/E, while ALNY leads on capital efficiency and profitability with 21.3% ROIC and 81.8% gross margin. UTHR currently holds the highest overall quantitative score in the immediate peer group at 83/100 (A-) compared with VTRS at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VTRS ACTIVE Viatris Inc.	D+	57/100	—	35.2%	-8.1%	-1.92%	$21.86B	Benchmark Subject
ALNY Alnylam Pharmaceuticals Inc.	D+	53/100	74.2x	81.8%	21.3%	-4.24%	$22.10B	/alny-vs-vtrs →
INSM Insmed Incorporated	D	44/100	—	79.7%	-35.0%	-2.90%	$24.70B	/insm-vs-vtrs →
UTHR United Therapeutics Corporation	A-	83/100	19.1x	87.9%	20.1%	-0.43%	$25.68B	/uthr-vs-vtrs →
ROIV Roivant Sciences Ltd.	D-	42/100	—	—	-14.0%	-2.76%	$26.66B	/roiv-vs-vtrs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001792044

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viatris Inc. (VTRS) reported GAAP revenue of $14.25B (-3.0% vs. FY2024 revenue of $14.69B , and -7.4% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $2.32B, and free cash flow of $1.94B (-2.0% YoY). On the balance sheet, VTRS closed FY2025 with $37.19B in total assets against $12.48B in total debt (Altman Z-Score: 0.81, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$14.25B	$0	$2.32B	$1.94B	$37.19B	$12.48B
FY2024 (FY)	2024-12-31	$14.69B	$0	$2.30B	$1.98B	$41.50B	$14.04B
FY2023 (FY)	2023-12-31	$15.39B	$0	$2.90B	$2.21B	$18.47B	$4.32B

3. VTRS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VTRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does VTRS compare to ALNY and INSM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for VTRS?

Where is VTRS trading relative to its 50-day, 200-day, and 52-week technical levels?

VTRS last traded at $18.67 (-1.92% on volume of 7,246,785 shares), positioning the stock +6.02% above its 50-day simple moving average ($17.61) and +16.76% above its 200-day simple moving average ($15.99). Across its 52-week range of $9.92 to $19.51, VTRS sits at the 91.2% percentile with a 14-day RSI of 62.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.4% ($17.66 to $19.68).

Direct Sub-Reports: VTRS RQD Cockpit VTRS 12M Forecast VTRS Earnings & Move VTRS Dividends & DRIP VTRS Insiders & 13F VTRS Whale Options VTRS Profit Sankey VTRS News & Why

ROARABLE RATING BRIEF • RQD 57/100 (D+) ✓ SEC XBRL & RQD VERIFIED

VTRS — Viatris Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Viatris Inc. (VTRS) earns a live Roarable RQD composite score of 57/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $18.67 (-1.92% 1D, market capitalization $21.86B).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -8.1%, gross margin of 35.2%, operating margin of -18.7%, and free cash flow yield of 8.78%.
Whale 13F & Options Flow (18/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (12/20) + Forensic Balance Sheet (12/20): Incorporates a 1.15x equity beta, Altman Z-Score of 0.81, Piotroski F-Score of 6/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Viatris Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $22.1B. — for specifics on products, customers, or revenue mix beyond the sector and industry classification.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Viatris Inc. (VTRS) reported $14.25B in annual revenue (up from $14.69B in FY2024, -3.0% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($15.39B revenue, $0 net income) through FY2025, VTRS scaled operating cash flow to $2.32B and free cash flow to $1.94B, backed by $37.19B in total assets against $12.48B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D+ • RQD 57/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 8.78% and institutional whale pillar of 18/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 18/20, sustained execution supports upside toward the upper end of the $9.92 – $19.51 52-week range.
🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh current valuation against -18.7% operating margins and a 1.15x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector-level context is the Health Care classification. — for any ripple effects beyond this.

Key Question #1: Can VTRS sustain or expand its -18.7% operating margin and -8.1% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $14.25B and free cash flow of $1.94B, how will capital allocation balance growth reinvestment against $12.48B in total debt?
Key Question #3: How sensitive is VTRS's 33.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.15x)?

VTRS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Viatris Inc. (VTRS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VTRS Debate Forum (3) ↓

🟡 MARKET WIRE Viatris • 21h ago

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Viatris report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Should Value Investors Buy Viatris (VTRS) Stock?

Yahoo Finance report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Viatris To Acquire Pacira BioSciences - What Investors Should Know (NASDAQ:VTRS)

Seeking Alpha report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

Viatris Inc (VTRS) Shares Surge 4.5% -- What GF Score of 63 Tells Investors

GuruFocus report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus

Yahoo Finance report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Why Is Pacira BioSciences Stock Skyrocketing Thursday? - Viatris (NASDAQ:VTRS), Pacira BioSciences (NASDA

Benzinga report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 1d ago

Viatris: Improved Confidence Drives M&A Action Again (NASDAQ:VTRS)

Seeking Alpha report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Viatris (NASDAQ:VTRS) Vs The Rest Of The Pack

Yahoo Finance report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VTRS Bull vs. Bear Conversation Board — What's Your Call at $18.67?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VTRS 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $23.42 (+23.0%)

📌 Pinned Debate

Institutional accumulation and options positioning score 18 of 20 in the Roarable RQD rating, the strongest pillar in the data.

The street is overcomplicating Viatris Inc. (VTRS). Institutional accumulation and options positioning score 18 of 20 in the Roarable RQD rating, the strongest pillar in the data.. With an RQD score of 57/100 (D+) and Forensic Balance Sheet at 8/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $20.56.

CapAlloc_Nerd 🐂 BULL

@MidwestValue Agree on the RQD 57/100 quality, though with 1.15 beta I'm scaling in with half-size at $19.04 and keeping dry powder in case we test $17.71.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $14.28 (-25.0%)

Spot @ $19.04

An Altman Z-Score of 0.81 and ROIC of -8.1% signal weak balance-sheet and operating returns against a forward P/E of 33.

Sitting on the sidelines or leaning short VTRS above $19.04. An Altman Z-Score of 0.81 and ROIC of -8.1% signal weak balance-sheet and operating returns against a forward P/E of 33.. Until Fundamental Cash Engine (7/20) and FCF yield (8.78%) inflect higher, upside is capped near $19.51.